MX2009006794A - Agonistas del receptor tirosina quinasa b para el tratamiento de trastornos autoinmunes. - Google Patents

Agonistas del receptor tirosina quinasa b para el tratamiento de trastornos autoinmunes.

Info

Publication number
MX2009006794A
MX2009006794A MX2009006794A MX2009006794A MX2009006794A MX 2009006794 A MX2009006794 A MX 2009006794A MX 2009006794 A MX2009006794 A MX 2009006794A MX 2009006794 A MX2009006794 A MX 2009006794A MX 2009006794 A MX2009006794 A MX 2009006794A
Authority
MX
Mexico
Prior art keywords
agonists
autoimmune disorders
trkb
treating autoimmune
trkb agonists
Prior art date
Application number
MX2009006794A
Other languages
English (en)
Inventor
Chia-Yang Lin
Hua Long
David Tsao
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of MX2009006794A publication Critical patent/MX2009006794A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan agonistas de receptor tirosina quinasa (TrkB) para reducir la invasión leucocitaria del sistema nervioso central en enfermedades autoinmunes tales como esclerosis múltiple; los agonistas de TrkB incluyen agonistas de origen natural, tales como NT4 y BDNF, así como agonistas tales como anticuerpos agonistas.
MX2009006794A 2006-12-20 2007-12-05 Agonistas del receptor tirosina quinasa b para el tratamiento de trastornos autoinmunes. MX2009006794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87091806P 2006-12-20 2006-12-20
PCT/IB2007/004145 WO2008078179A1 (en) 2006-12-20 2007-12-05 Trkb agonists for treating autoimmune disorders

Publications (1)

Publication Number Publication Date
MX2009006794A true MX2009006794A (es) 2009-07-02

Family

ID=39186034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006794A MX2009006794A (es) 2006-12-20 2007-12-05 Agonistas del receptor tirosina quinasa b para el tratamiento de trastornos autoinmunes.

Country Status (12)

Country Link
US (1) US20100086997A1 (es)
EP (1) EP2114436A1 (es)
JP (1) JP2010513461A (es)
KR (1) KR20090091181A (es)
CN (1) CN101605556A (es)
AU (1) AU2007337809A1 (es)
BR (1) BRPI0720473A2 (es)
CA (1) CA2672750A1 (es)
IL (1) IL199017A0 (es)
MX (1) MX2009006794A (es)
RU (1) RU2009123491A (es)
WO (1) WO2008078179A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5674469B2 (ja) * 2007-10-11 2015-02-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
CN102645542A (zh) * 2012-04-20 2012-08-22 苏州大学 Bdnf酶联免疫测定试剂盒
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
CN102901815B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体816/817位酪氨酸位点活性的ELISA试剂盒及其使用方法
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
KR20180037994A (ko) 2015-07-28 2018-04-13 오토노미, 인코포레이티드 TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
US11078287B2 (en) 2015-11-17 2021-08-03 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
US10793634B2 (en) * 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
EP3677280A4 (en) * 2017-08-28 2021-05-12 Shanghai Yile Biotechnology Co., Ltd. POLYPEPTIDE AND ANTIBODIES LINKED TO A POLYPEPTIDE
WO2019108662A1 (en) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use
WO2023072877A1 (en) * 2021-10-25 2023-05-04 Ellennbe Gmbh Pharmaceutical composition and kit comprising an immunomodulatory substance for treating diseases
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF
CN118265719A (zh) * 2022-03-30 2024-06-28 肽梦想株式会社 具有TrkB结合活性的肽复合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ATE219519T1 (de) * 1989-01-23 2002-07-15 Chiron Corp Rekombinanttherapien für infektionen und hyperproliferative störungen
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6566091B1 (en) * 1990-09-25 2003-05-20 Genentech, Inc. Neurotrophic factor
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US6506728B2 (en) * 1990-09-25 2003-01-14 Genentech, Inc. Methods using a novel neurotrophic factor, NT-4
AU654302B2 (en) * 1990-09-25 1994-11-03 Genentech Inc. Novel neurothrophic factor
EP0644937A4 (en) * 1992-06-12 1995-05-03 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression.
AU674881B2 (en) * 1992-09-07 1997-01-16 Biotechnology And Biological Sciences Research Council, The Growth hormone potentiating molecules
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
IL109280A0 (en) * 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression
US6024734A (en) * 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US20030191061A1 (en) * 1994-03-31 2003-10-09 Brewitt Barbara A. Treatment methods using homeopathic preparations of growth factors
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
TR199901734T2 (xx) * 1996-11-15 2000-01-21 Genentech, Inc. N�rotrofinlerin ar�t�lmas�.
US6391312B1 (en) * 1997-01-23 2002-05-21 Sumitomo Pharmaceuticals Co., Limited Remedies for diabetes
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US6365373B2 (en) * 1997-04-25 2002-04-02 Genentech, Inc. Nucleic acids encoding NGF variants
US7452863B1 (en) * 1997-04-29 2008-11-18 Genentech, Inc. NGF variants
AU766579B2 (en) * 1997-08-29 2003-10-16 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
AU9692198A (en) * 1997-10-10 1999-05-03 Kevin J. Donahue Gene delivery compositions and methods
JP2003503484A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド アミノアルキル誘導体
JP2003503500A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド 神経学的疾患の治療のためのキヌクリジン誘導体
PT1223966E (pt) * 1999-10-29 2003-09-30 Biopharm Ges Biotechn Entwickl Utilizacao do gdnf para tratamento de defeitos na cornea
WO2001060398A1 (fr) * 2000-02-18 2001-08-23 Sumitomo Pharmaceuticals Company, Limited Medicaments destines a ameliorer l'intolerance au glucose
WO2001066133A1 (fr) * 2000-03-06 2001-09-13 Sumitomo Pharmaceuticals Company, Limited Agents d'amelioration de la resistance a la leptine
US7060429B2 (en) * 2001-02-22 2006-06-13 University Of Maryland, Baltimore Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
CA2450074A1 (en) * 2001-06-14 2002-12-27 Vertex Pharmaceuticals Incorporated Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
JP2007522204A (ja) * 2004-02-11 2007-08-09 ペインセプター ファーマ コーポレーション ニューロトロフィンが媒介する活性を調節する方法
JP2008545781A (ja) * 2005-06-06 2008-12-18 ワイス 抗ＴｒｋＢモノクローナル抗体およびその使用
EP2526942B1 (en) * 2005-06-08 2017-08-09 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
RU2008131939A (ru) * 2006-02-02 2010-02-10 Ринат Ньюросайенс Корп. (Us) Способы лечения нежелательной потери веса или нарушений приема пищи агонистами trkb

Also Published As

Publication number Publication date
KR20090091181A (ko) 2009-08-26
EP2114436A1 (en) 2009-11-11
US20100086997A1 (en) 2010-04-08
RU2009123491A (ru) 2010-12-27
IL199017A0 (en) 2010-02-17
BRPI0720473A2 (pt) 2014-01-14
CA2672750A1 (en) 2008-07-03
JP2010513461A (ja) 2010-04-30
WO2008078179A1 (en) 2008-07-03
CN101605556A (zh) 2009-12-16
AU2007337809A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
MX2009006794A (es) Agonistas del receptor tirosina quinasa b para el tratamiento de trastornos autoinmunes.
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
MXPA05013364A (es) Procedimiento para preparar 3-benzazepinas.
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
EP1993560A4 (en) CANNABINOID RECEPTOR ANTAGONISTS / INVERSE AGONISTS TO TREAT OVERWEIGHT
ATE469895T1 (de) Cgrp-rezeptorantagonisten
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
WO2007149427A3 (en) Tyrosine kinase inhibitors
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
BRPI0519708A2 (pt) compostos de indazol-carboxamida
EP1606264A4 (en) ANTAGONISTS OF MONOCYCLIC SPIROHYDANTOIN ANILIDE CGRP RECEPTORS
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
ATE524445T1 (de) Benzocycloheptapyridine als inhibitoren der tyrosinkinase met
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
TW200621244A (en) Modulators of muscarinic receptors
ATE321047T1 (de) Tricyclische diazepine als tocolytische oxytocin rezeptor antagonisten
EA200970303A1 (ru) Тиазолпиразолопиримидин в качестве антагониста рецептора крф1
TW200531679A (en) Methods of modulating cytokine activity; related reagents
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
WO2005030678A3 (en) AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS
TW200800959A (en) Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal